Page last updated: 2024-10-26

valproic acid and Cancer of Head

valproic acid has been researched along with Cancer of Head in 9 studies

Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.

Research Excerpts

ExcerptRelevanceReference
"Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage."6.82Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016)
"Recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has a poor prognosis and the combination of cisplatin and cetuximab, with or without 5-fluorouracil, is the gold standard treatment in this stage."2.82Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. ( Aversa, C; Botti, G; Bruzzese, F; Budillon, A; Calogero, E; Caponigro, F; Cavalcanti, E; D'Aniello, R; Daponte, A; De Cecio, R; De Feo, G; Di Gennaro, E; Di Marzo, M; Ionna, F; Longo, F; Losito, NS; Maglione, MG; Maiolino, P; Montano, M; Muto, P; Pavone, E; Perri, F; Petrillo, A; Pontone, M; Sandomenico, F; Scala, S; Trotta, A; Zotti, AI, 2016)
"Valproic acid is an antiepileptic drug with more than 50 years of clinical use."2.61El ácido valproico como agente sensibilizador al tratamiento anticáncer. ( Correa-Basurto, J; Luna-Palencia, GR; Vásquez-Moctezuma, I, 2019)
"Growth inhibition profiles of HNSCC cell lines varied in response to VPA."1.38Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. ( Cheong, SC; Gan, CP; Hamid, S; Hor, SY; Ismail, SM; Saunders, N; Teo, SH; Wan Mustafa, WM; Zain, RB, 2012)

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's7 (77.78)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Luna-Palencia, GR1
Correa-Basurto, J1
Vásquez-Moctezuma, I1
Gama, RR1
Arantes, LMRB1
Sorroche, BP1
De Marchi, P1
Melendez, ME1
Carvalho, RS1
de Lima, MA1
Vettore, AL1
Carvalho, AL1
Lee, BS1
Kim, YS2
Kim, HJ1
Kim, DH1
Won, HR1
Kim, CH1
Kang, H1
Gillespie, TW1
Goodman, M1
Brodie, SA1
Brandes, M1
Ribeiro, M1
Ramalingam, SS1
Shin, DM1
Khuri, FR1
Brandes, JC1
Lee, SH1
Nam, HJ1
Kang, HJ1
Samuels, TL1
Johnston, N1
Lim, YC1
Caponigro, F1
Di Gennaro, E1
Ionna, F1
Longo, F1
Aversa, C1
Pavone, E1
Maglione, MG1
Di Marzo, M1
Muto, P1
Cavalcanti, E1
Petrillo, A1
Sandomenico, F1
Maiolino, P1
D'Aniello, R1
Botti, G1
De Cecio, R1
Losito, NS1
Scala, S1
Trotta, A1
Zotti, AI1
Bruzzese, F1
Daponte, A1
Calogero, E1
Montano, M1
Pontone, M1
De Feo, G1
Perri, F1
Budillon, A1
Kothari, V1
Joshi, G1
Nama, S1
Somasundaram, K1
Mulherkar, R1
Gan, CP1
Hamid, S1
Hor, SY1
Zain, RB1
Ismail, SM1
Wan Mustafa, WM1
Teo, SH1
Saunders, N1
Cheong, SC1
Erlich, RB1
Rickwood, D1
Coman, WB1
Saunders, NA1
Guminski, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736]Early Phase 142 participants (Actual)Interventional2015-12-31Completed
Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT02624128]Phase 239 participants (Anticipated)Interventional2015-02-23Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for valproic acid and Cancer of Head

ArticleYear
El ácido valproico como agente sensibilizador al tratamiento anticáncer.
    Gaceta medica de Mexico, 2019, Volume: 155, Issue:4

    Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Ne

2019

Trials

2 trials available for valproic acid and Cancer of Head

ArticleYear
Evaluation of acetylation and methylation in oral rinse of patients with head and neck cancer history exposed to valproic acid.
    Scientific reports, 2021, 08-12, Volume: 11, Issue:1

    Topics: Acetylation; DNA Methylation; Double-Blind Method; Female; Head and Neck Neoplasms; Histones; Humans

2021
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    BMC cancer, 2016, 11-25, Volume: 16, Issue:1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetu

2016

Other Studies

6 other studies available for valproic acid and Cancer of Head

ArticleYear
HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells.
    Scientific reports, 2018, 08-21, Volume: 8, Issue:1

    Topics: Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Syner

2018
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
    Cancer, 2014, May-01, Volume: 120, Issue:9

    Topics: Carcinoma, Squamous Cell; Cohort Studies; Enzyme Inhibitors; Female; Head and Neck Neoplasms; Histon

2014
Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells.
    Oncology reports, 2015, Volume: 34, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce

2015
HDAC inhibitor valproic acid enhances tumor cell kill in adenovirus-HSVtk mediated suicide gene therapy in HNSCC xenograft mouse model.
    International journal of cancer, 2010, Feb-01, Volume: 126, Issue:3

    Topics: Adenoviruses, Human; Animals; Bystander Effect; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined

2010
Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence.
    Head & neck, 2012, Volume: 34, Issue:3

    Topics: Antineoplastic Agents; Azacitidine; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Differen

2012
Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:3

    Topics: Acetylation; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Prolifer

2009